Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Neoleukin Therapeutics, Inc. | d882730d10k.htm |
| EX-31.2 - EX-31.2 - Neoleukin Therapeutics, Inc. | d882730dex312.htm |
| EX-21.1 - EX-21.1 - Neoleukin Therapeutics, Inc. | d882730dex211.htm |
| EX-23.1 - EX-23.1 - Neoleukin Therapeutics, Inc. | d882730dex231.htm |
| EX-10.8 - EX-10.8 - Neoleukin Therapeutics, Inc. | d882730dex108.htm |
| EX-32.1 - EX-32.1 - Neoleukin Therapeutics, Inc. | d882730dex321.htm |
| EX-4.3 - EX-4.3 - Neoleukin Therapeutics, Inc. | d882730dex43.htm |
| EX-31.1 - EX-31.1 - Neoleukin Therapeutics, Inc. | d882730dex311.htm |
Exhibit 32.2
NEOLEUKIN THERAPEUTICS, INC.
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Neoleukin Therapeutics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kamran Alam, Interim Chief Financial Officer of the Company, certify, pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| /s/ Kamran Alam |
| Kamran Alam Interim Chief Financial Officer |
March 12, 2020
This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Neoleukin Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.
127